Encompass Health Corporation
EHCNYSEOther · Services-Hospitals · SEC filings ↗ · Compare ⊕
View price & chart on Yahoo Finance ↗Financials
SEC XBRL · annual| FY25 | FY24 | FY23 | FY22 | FY21 | FY20 | |
|---|---|---|---|---|---|---|
| Revenue | $5.94B | $5.37B | $4.80B | $4.35B | $4.01B | $3.57B |
| Operating income | — | — | — | $131.5M | $143.0M | $159.3M |
| Net income | $566.2M | $455.7M | $352.0M | $271.0M | $412.2M | $284.2M |
| Total assets | $7.09B | $6.53B | $6.10B | $5.64B | $6.86B | $6.45B |
| Total liabilities | $3.81B | $3.69B | $3.81B | $3.77B | $4.47B | $4.44B |
| Equity | $2.44B | $2.07B | $1.65B | $1.31B | $1.91B | $1.59B |
| EPS (diluted) | $5.54 | $4.46 | $3.47 | $2.70 | $4.11 | $2.85 |
| Shares out. | 100.7M | 100.1M | 99.7M | 99.4M | 99.3M | 98.4M |
Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.
Key ratios
from filings · FY2025- Operating margin
- —
- Net margin
- 9.5%
- Return on equity
- 23.2%
- Return on assets
- 8.0%
- Return on capital (ROCE)
- —
- Liabilities / assets
- 53.8%
- Debt / equity
- 1.56×
- Book value / share
- $24.21
- Revenue growth (YoY)
- 10.5%
- Net income growth (YoY)
- 24.2%
Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.
Financial health
forensic scores · FY2025- Accruals / assets
- −8.6%clean
- Piotroski F-Score
- 7/8strong
Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.
Quality score
EDS ScoreOur own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.
Signs
● 4 good- Strong return on equity (>15%)
- Revenue is growing year-over-year
- Positive operating cash flow
- Clean earnings (low accruals)
Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.
5%+ owners
SEC Schedule 13D / 13G · last 3 yrs- Vanguard Portfolio Management LlcPassive (13G)Apr 29, 2026
- Vanguard Capital Management LlcPassive (13G)Apr 29, 2026
- Vanguard Group IncPassive (13G)Mar 26, 2026
- Invesco Ltd.Passive (13G)Feb 12, 2026
- Wellington Management Group LlpPassive (13G)Feb 10, 2025
Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.
Insider transactions
SEC Form 4 · most recent| Insider | Date | Type | Shares | Price |
|---|---|---|---|---|
| Coltharp Douglas EOfficer — EVP & Chief Financial Officer | May 15, 2026 | Option exercise | 27,694 | $32.94 |
| Tuer Patrick WilliamOfficer — EVP, Chief Operating Officer | May 11, 2026 | Sell | 682 | $104.56 |
| O'Connor Kevin J.Director | May 7, 2026 | Grant | 1,634 | $0.00 |
| Christie Edward M IiiDirector | May 7, 2026 | Grant | 1,634 | $0.00 |
| Reidy Christopher RDirector | May 7, 2026 | Grant | 1,634 | $0.00 |
| Hayes Cain ADirector | May 7, 2026 | Grant | 1,634 | $0.00 |
| Carmichael Greg DDirector | May 7, 2026 | Grant | 1,634 | $0.00 |
| Williams TerranceDirector | May 7, 2026 | Grant | 1,634 | $0.00 |
| Katz Leslye GDirector | May 7, 2026 | Grant | 1,634 | $0.00 |
| Herman Joan EDirector | May 7, 2026 | Grant | 1,634 | $0.00 |
| Schlichting Nancy MDirector | May 7, 2026 | Grant | 1,634 | $0.00 |
| Carmichael Greg DDirector | Apr 15, 2026 | Grant | 27 | $0.00 |
Headline trade per Form 4 (officers, directors, 10%+ owners). Buy/sell read from the filing's structured data — blank where a field isn't cleanly tagged.
Short interest
FINRA · bi-monthly| Settlement | Shares short | Days to cover | Δ vs prior |
|---|---|---|---|
| May 15, 2026 | 3.4M | 3.3 | +0.0% |
| Apr 30, 2026 | 3.4M | 3.6 | +11.6% |
| Apr 15, 2026 | 3.1M | 2.8 | -9.1% |
| Mar 31, 2026 | 3.4M | 3.9 | -4.9% |
| Mar 13, 2026 | 3.5M | 3.7 | -0.5% |
Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.
Material events
SEC Form 8-K · most recent- Entered a material agreement · New financial obligationJun 1, 2026
- Entered a material agreement · Other material eventMay 15, 2026
- Shareholder voteMay 11, 2026
- Results of operations · Regulation FD disclosureApr 30, 2026
- Entered a material agreement · Terminated a material agreement · New financial obligationMar 10, 2026
- Results of operations · Regulation FD disclosureFeb 5, 2026
- Director / officer changeFeb 2, 2026
- Regulation FD disclosureDec 1, 2025
Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.
Recent SEC filings
All filings ↗- 8-KJun 1, 2026
- 4PRIMARY DOCUMENTMay 18, 2026
- 8-KMay 15, 2026
- 144May 15, 2026
- 4PRIMARY DOCUMENTMay 12, 2026
- 144May 11, 2026
- 8-KMay 11, 2026
- 4PRIMARY DOCUMENTMay 11, 2026
- 4PRIMARY DOCUMENTMay 11, 2026
- 4PRIMARY DOCUMENTMay 11, 2026
- 4PRIMARY DOCUMENTMay 11, 2026
- 4PRIMARY DOCUMENTMay 11, 2026
- 4PRIMARY DOCUMENTMay 11, 2026
- 4PRIMARY DOCUMENTMay 11, 2026
- 4PRIMARY DOCUMENTMay 11, 2026
Corporate family
Spin-offs from Encompass Health Corporation (1)
- Enhabit, Inc.EHABcompletedJul 1, 2022details
From the spin-off filings we track. Follow a company to walk its own history.